APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
S. 4683, the National Defense Authorization Act for Fiscal Year 2025, Section 887, Requirement to produce domestically produced generic drugs, provisions relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; Federal policy relating to providing tax incentives to spur domestic manufacturing of generic drugs; and Federal policy related to Administration for Strategic Preparedness and Response initiatives to strengthen domestic pharmaceutical manufacturing capabilities.
Foreign entity interest: Artemis Parent, Inc., Artemis Intermediate Holdings, Inc., and Apotex Holdco Inc., the parent companies of Apotex Corp., and Apotex Inc., its affiliate, identified by the registrants first quarter 2024 LD-2 report, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Health Issues HCR
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships will North American and other allied countries; Draft Senate Finance Committee drug shortage legislation, provisions relating to Medicare reimbursement policies for generic drugs; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings;
Foreign entity interest: Artemis Parent, Inc., Artemis Intermediate Holdings, Inc., and Apotex Holdco Inc., the parent companies of Apotex Corp., and Apotex Inc., its affiliate, identified by the registrants first quarter 2024 LD-2 report, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.